Local biotech firm Moderna Inc. has indicated its COVID-19 vaccine could be one of the most expensive in the industry.
Executives from the Cambridge-based company discussed the commercialization plans for its COVID-19 vaccine, mRNA-1273, and other business updates during the company's second quarter earnings call Wednesday.
There were four key takeaways from the call.
